Cardiol Therapeutics Inc. launched a public offering of Class A common shares, dated October 8, 2024. The offering, conducted concurrently in the United States and Canada (excluding Québec), involves shares priced through arm's length negotiations with underwriters, based on prevailing market conditions. Canaccord Genuity LLC is the lead underwriter for the U.S., while Canaccord Genuity Corp. manages Canadian sales. The offering allows for an over-allotment option, enabling underwriters to purchase additional shares to cover potential over-allotments. Legal advisors include Borden Ladner Gervais LLP for Cardiol in Canadian matters and Troutman Pepper Hamilton Sanders LLP for U.S. aspects. The underwriters are represented by Stikeman Elliott LLP (Canada) and Goodwin Procter LLP (U.S.). Proceeds are intended for the development of CardiolRx™ in treating recurrent pericarditis, as well as for general corporate purposes. The offering is anticipated to close shortly after pricing, with shares trading on both the Toronto Stock Exchange and Nasdaq under the symbol “CRDL”.?